Trial Profile

Safety and Immunogenicity of a Second Generation Shigella Bioconjugate Vaccine: a Phase II Randomized, Controlled, and Blinded Study in 9-month-old Infants

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 26 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

07 May 2025 According to the Valneva Media Release, results for this study are expected in the second half of 2025.
09 Apr 2025 According to the Valneva Media Release, company announced that its first participant has been vaccinated in a Phase 2 infant safety and immunogenicity study of Shigella4V2 the worlds most clinically advanced tetravalent bioconjugate vaccine candidate against shigellosis.
09 Apr 2025 Planned End Date changed from 1 Nov 2025 to 1 Feb 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com